Compare TY & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TY | PGEN |
|---|---|---|
| Founded | 1929 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | N/A | N/A |
| Metric | TY | PGEN |
|---|---|---|
| Price | $33.17 | $4.93 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | 43.0K | ★ 3.4M |
| Earning Date | 01-01-0001 | 03-18-2026 |
| Dividend Yield | ★ 3.36% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 4.78 | N/A |
| Revenue | N/A | ★ $6,309,000.00 |
| Revenue This Year | N/A | $342.78 |
| Revenue Next Year | N/A | $478.46 |
| P/E Ratio | $6.38 | ★ N/A |
| Revenue Growth | N/A | ★ 59.20 |
| 52 Week Low | $25.16 | $1.11 |
| 52 Week High | $30.73 | $5.23 |
| Indicator | TY | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 49.04 | 58.55 |
| Support Level | $32.82 | $4.41 |
| Resistance Level | $33.69 | $5.00 |
| Average True Range (ATR) | 0.35 | 0.38 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 40.23 | 90.00 |
Tri-Continental Corp is a United States-based closed-end management investment company. It invests to produce future growth of both capital and income while providing reasonable current income. The fund is divided into two equal segments namely, the equity segment uses quantitative models to select individual stocks whereas the Flexible capital income segment invests across a company's investable capital structure, including stocks, bonds, and convertible securities. The Fund invests in a range of sectors, which include consumer discretionary, consumer staples, energy, financials, healthcare, industrials, information technology, industrials, materials, real estate, telecommunication services, utilities, aerospace and defense, banking, chemicals, and others.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.